Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
AIDS Behav ; 27(7): 2131-2162, 2023 Jul.
Article de Anglais | MEDLINE | ID: mdl-36538138

RÉSUMÉ

Optimal adherence to pre-exposure prophylaxis (PrEP) is critical, but challenging. Men who have sex with men and transgender women have high rates of HIV incidence and substance use. Substance use is associated with reduced adherence to other medications, but associations between substance use and adherence to PrEP are less clear. Thus, the current review 1) systematically evaluates the measurement of substance use and PrEP adherence in studies examining both and 2) summarizes reported findings. Peer-reviewed articles published between 2010 - April 2021 examining associations between substance use and PrEP adherence were reviewed. Fifty studies met inclusion criteria. Assessment of substance use (i.e., mostly via self-reports at baseline) and PrEP adherence (i.e., often via tenofovir diphosphate [TFV-DP] concentration levels at follow-up) varied considerably across studies. Many studies used categorical variables (e.g., substance use: yes/no). Studies using TFV-DP levels defined adherence consistently (i.e., TFV-DP ≥ 700 fmol/punch), with slight variations. Qualitative studies (n = 10) indicated that substance use (mainly alcohol) is related to poorer PrEP adherence. While quantitative findings to date are equivocal for alcohol, there is a pattern of findings linking stimulant use with poorer PrEP adherence. This review reveals four methodological gaps, which can be addressed in future research by: 1) use of uniform benchmarks for substance use measures, 2) prospective assessment for substance use, 3) use of continuous outcome variables wherever possible, and 4) more extensive consideration of potential confounders. Addressing these methodological gaps may help us reach more definitive conclusions regarding associations between substance use and PrEP adherence.


Sujet(s)
Agents antiVIH , Infections à VIH , Prophylaxie pré-exposition , Minorités sexuelles , Troubles liés à une substance , Personnes transgenres , Mâle , Humains , Femelle , Infections à VIH/épidémiologie , Infections à VIH/prévention et contrôle , Infections à VIH/traitement médicamenteux , Homosexualité masculine , Ténofovir/usage thérapeutique , Études prospectives , Adhésion au traitement médicamenteux , Troubles liés à une substance/épidémiologie , Agents antiVIH/usage thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE